Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global norms, local institutions: a controlled comparative case study of WHO essential medicines policy adoption in Eastern Europe.

Globalization and health·2026
Same author

Mind the governance gap: a one health scoping review of national AMR performance indicators.

npj antimicrobials and resistance·2026
Same author

Patient-physician sex concordance in cardiovascular care: context matters.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Best practices along the kidney transplantation clinical journey.

Frontiers in transplantation·2026
Same author

Omission and hallucination prevalence of clinical guidelines in diagnostic large language model outputs.

BMJ health & care informatics·2026
Same author

Integrating financial risk into cardiometabolic prevention: From price transparency to patient-level insights into diabetes-related spending.

American journal of preventive cardiology·2026

Related Experiment Video

Updated: Jul 11, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Stimulating pharmaceutical research and development for neglected diseases.

Monique F Mrazek1, Elias Mossialos

  • 1LSE Health and Social Care, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, UK. m.f.mrazek@lse.ac.uk

Health Policy (Amsterdam, Netherlands)
|March 20, 2003
PubMed
Summary

New vaccines and drug treatments are urgently needed for neglected diseases (NDs) in low-income countries. Current research and development (R&D) efforts, primarily through public-private partnerships, require careful consideration of incentives for pharmaceutical companies.

More Related Videos

Optimization and Utilization of Agrobacterium-mediated Transient Protein Production in Nicotiana
23:21

Optimization and Utilization of Agrobacterium-mediated Transient Protein Production in Nicotiana

Published on: April 19, 2014

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates
13:55

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates

Published on: January 27, 2019

Related Experiment Videos

Last Updated: Jul 11, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Optimization and Utilization of Agrobacterium-mediated Transient Protein Production in Nicotiana
23:21

Optimization and Utilization of Agrobacterium-mediated Transient Protein Production in Nicotiana

Published on: April 19, 2014

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates
13:55

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates

Published on: January 27, 2019

Area of Science:

  • Global Health
  • Infectious Diseases
  • Pharmaceutical R&D

Background:

  • Neglected diseases (NDs) cause significant mortality and morbidity in impoverished nations.
  • Existing treatments are often inadequate due to bacterial resistance, toxicity, or lack of availability.
  • Current R&D for NDs is largely driven by public and non-profit sectors via public-private partnerships.

Purpose of the Study:

  • To highlight the critical need for novel vaccines and drugs against neglected diseases.
  • To examine current R&D strategies and proposed incentives for pharmaceutical industry involvement.
  • To emphasize the importance of R&D within a broader public health and access-to-medicines framework.

Main Methods:

  • Review of current initiatives and strategies for neglected disease R&D.
  • Analysis of proposed push and pull mechanisms to stimulate pharmaceutical industry engagement.
  • Discussion of the interplay between R&D, access to medicines, and health system sustainability.

Main Results:

  • R&D for NDs is predominantly led by governmental, inter-governmental, and non-profit organizations through public-private partnerships.
  • Incentive mechanisms like push and pull funding for the pharmaceutical industry are proposed but warrant cautious evaluation.
  • Addressing R&D for NDs must be integrated with immediate concerns of medicine accessibility and health system strengthening.

Conclusions:

  • Urgent development of new vaccines and drugs is essential for combating neglected diseases.
  • Stimulating pharmaceutical R&D for NDs requires careful consideration of incentive models and public-private collaborations.
  • A comprehensive public health strategy must simultaneously address R&D, access to medicines, and health system sustainability in developing countries.